Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7039349 | 0.90 | ADRB3 (1.00) | ADRB3ADRB2 | |
| SCHEMBL7039345 | 0.90 | ADRB3 (1.00) | ADRB3ADRB2 | |
| SCHEMBL7040255 | 0.89 | ADRB3 (1.00) | ADRB3 | |
| SCHEMBL7037934 | 0.88 | ADRB3 (1.00) | ADRB3 | |
| SCHEMBL7042399 | 0.88 | ADRB3 (1.00) | ADRB3 | |
| Soterenol SCHEMBL1652640 | 0.86 | ADRB3 (0.95) | ADRB3ADRB2 | |
| Soterenol SCHEMBL119138 | 0.86 | ADRB3 (1.00) | ADRB3ADRB2 | |
| SCHEMBL7042103 | 0.85 | ADRB3 (1.00) | ADRB3 | |
| SCHEMBL7042110 | 0.85 | ADRB3 (1.00) | ADRB3 | |
| Soterenol SCHEMBL635183 | 0.85 | ADRB3 (0.97) | ADRB3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198330-B2 | Therapeutic or prophylactic agent for diabetes, obesity, dyslipidemia or metabolic syndrome comprising benzylamine derivative or pharmaceutically acceptable acid addition salt thereof | TORAY INDUSTRIES, INC. (JP) | 2012-06-12 | — | — | US | disclosed |
| US-20110124733-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR DIABETES, OBESITY, DYSLIPIDEMIA OR METABOLIC SYNDROME COMPRISING BENZYLAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID | TORAY INDUSTRIES, INC. (JP) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124733-A1 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR DIABETES, OBESITY, DYSLIPIDEMIA OR METABOLIC SYNDROME COMPRISING BENZYLAMINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID | GPR119, LIPC, LIPA | ADRB3 64/4885ADRB2 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.